En español
NIDA

Menu

NIDA Notes Articles: Treatment

NIDA Notes Category Graphic

Naltrexone via Skin Patch Proves Effectiveness of New Technology

November 2009

Reports on a new device that creates tiny painless punctures in the skin to allow medication to flow evenly from a skin patch into dermal capillaries and the bloodstream.

NIDA Notes Category Graphic

Nanotechnology Powers Smart Skin Patch

November 2011

An in vitro test demonstrates the potential of a programmable skin patch that will enable physicians to tailor transdermal medication doses to match patients' fluctuating needs.

NIDA Notes Category Graphic

New Therapy Reduces Drug Abuse Among Patients With Severe Mental Illness

June 2008

Describes a new intervention that enhances recovery prospects for substance abusers whose mental illness complicates the path toward recovery.

NIDA Notes Category Graphic

Nicotine Dependence is Linked With Mental Disorders in Pregnant Women

December 2008

Reports on a link between mental disorders, including mood, anxiety, or personality disorder and nicotine dependence in pregnancy women.

NIDA Notes Category Graphic

Oxycodone Vaccine Passes Early Tests

May 2013

A new vaccine hindered the often-abused prescription opioids oxycodone and hydrocodone from entering the brain and suppressed one of the drugs’ signature central nervous system effects. The findings warrant continued development of the vaccine as a potential aid in the treatment of oxycodone and hydrocodone abuse and dependence.

NIDA Notes Category Graphic

Patch Delivers Buprenorphine for Heroin Detox

November 2009

Describes research on the effectiveness of a buprenorphine patch to alleviate opioid withdrawal symptoms of newly abstinent heroin abusers.

NIDA Notes Category Graphic

Potential Pain Medication Targets Peripheral Nerves

September 2012

Researchers report a significant advance in the search for medications that can suppress pain but avoid opioids’ abuse potential and other undesirable CNS effects. A new compound reduces mouse responses in animal models of neurogenic and chronic inflammatory (e.g., arthritic) pain. The compound, called UB937, enhances the natural pain-killing activity of the neurotransmitter anandamide, and exerts its analgesic effects entirely in peripheral tissues, without entering the brain.

NIDA Notes Category Graphic

Prison Use of Medications for Opioid Addiction Remains Low

July 2011

Describes results from a nationwide survey among correctional facilities on the use of opioid replacement therapy for people who are addicted to heroin.

NIDA Notes Category Graphic

Receptor May Underlie Gender Differences in Response to Smoking Cessation

May 2013

Men benefit more than women from nicotine replacement therapy for smoking cessation because nicotine affects a key neuroreceptor differently in the two sexes, a NIDA-sponsored study suggests. The findings highlight the need for alternative therapies for women smokers, and point to the female hormone progesterone as a potential therapeutic target.

NIDA Notes Category Graphic

Recovery Checkup System Helps Substance Abusers Who Have Mental Disorders

December 2009

Reports on a posttreatment intervention to support recovery that may be especially beneficial for substance abusers with co-occurring mental disorders.

Pages

NIDA Notes

Tags

Drug Topics

Drugs of Abuse

Population Groups

Related Topics